Active Recombinant Human CD19 protein, His-tagged, R-PE labeled
Cat.No. : | CD19-3309HP |
Product Overview : | Recombinant Human CD19 protein, His-tagged was Conjugated with NH2-Reactive R-PE(R-Phycoerythrin). |
Availability | February 16, 2025 |
Unit | |
Price | |
Qty |
- Specification
- Gene Information
- Related Products
- Download
Source : | HEK293 |
Species : | Human |
Tag : | His |
Form : | Lyophilized from sterile 50 mM Tris, pH 8.0. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. |
Bio-activity : | Immobilized Human CD19 His at 2 μg/ml (100 μl/well) can bind Anti-CD19 Antibody, the EC50 of Anti-CD19 Antibody is 5-40 ng/mL. |
Molecular Mass : | The recombinant human CD19 consists of 283 amino acids and predictes a molecular mass of 31.6 kDa. In SDS-PAGE under reducing conditions, rhCD19 migrates as an approximately 47 kDa band due to glycosylation. |
Protein length : | Met1-Lys291 |
Endotoxin : | < 1.0 EU per μg protein as determined by the LAL method. |
Purity : | > 90 % as determined by SDS-PAGE. |
Storage : | Samples are stable for up to twelve months from date of receipt at -20°C to -80°C Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
Reconstitution : | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents. |
Publication : |
Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization (2019)
Development of a cGMP-compliant process to manufacture donor-derived, CD45RA-depleted memory CD19-CAR T cells (2022)
Transient blockade of TBK1/IKKε allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors (2021)
Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy (2023)
Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells (2017)
|
Gene Name : | CD19 CD19 molecule [ Homo sapiens ] |
Official Symbol : | CD19 |
Synonyms : | CD19; CD19 molecule; CD19 antigen; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4; B4; CVID3; MGC12802; |
Gene ID : | 930 |
mRNA Refseq : | NM_001178098 |
Protein Refseq : | NP_001171569 |
MIM : | 107265 |
UniProt ID : | P15391 |
Products Types
◆ Recombinant Protein | ||
CD19-127H | Recombinant Human CD19 Protein, Fc-tagged, Biotinylated | +Inquiry |
CD19-130H | Recombinant Human CD19 Protein, Fc-tagged | +Inquiry |
CD19-2947H | Recombinant Human CD19 protein, His-tagged, Site-Specific AF 488-Labeled | +Inquiry |
CD19-05H | Active Recombinant Human CD19 Protein, Fc-tagged, Alexa Fluor® 488 conjugated | +Inquiry |
CD19-3083H | Recombinant Human CD19 protein, His-tagged | +Inquiry |
◆ Lysates | ||
CD19-2164MCL | Recombinant Mouse CD19 cell lysate | +Inquiry |
Related Gene
Not For Human Consumption!
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewThe manufacturer of CD19 protein has consistently provided outstanding technical support that has surpassed my expectations.
This protein demonstrates remarkable purity, stability, and specificity, ensuring utmost accuracy and reproducibility in my research endeavors.
Their dedication to customer satisfaction has been instrumental in overcoming obstacles and achieving successful results in my experiments.
Q&As (5)
Ask a questionCAR-T cells are engineered to express a receptor that recognizes CD19 on the surface of cancerous B cells. When they encounter these cells, they destroy them.
CD19 deficiencies can lead to primary immunodeficiencies, making individuals more susceptible to infections.
Side effects may include cytokine release syndrome (CRS), neurologic toxicity, and long-term B-cell aplasia.
CAR-T cell therapy is used to treat B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma.
CAR-T cell therapy has shown remarkable effectiveness in inducing remissions in patients with CD19-positive malignancies, particularly in those who have relapsed or failed conventional treatments.
Ask a Question for All CD19 Products
Required fields are marked with *
My Review for All CD19 Products
Required fields are marked with *
Inquiry Basket